Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...1213141516171819202122...3536»
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC (clinicaltrials.gov) -  Jul 14, 2022   
    P2,  N=3, Terminated, 
    Trial completion date: Feb 2026 --> Jul 2026 | Trial primary completion date: Feb 2026 --> Jul 2026 Trial completion date: Jan 2023 --> May 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2022 --> May 2022; Lack of Interest
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Libtayo (cemiplimab-rwlc) / Regeneron, Tafinlar (dabrafenib) / Novartis, BeiGene
    Trial completion date, Trial primary completion date, IO biomarker:  Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer (clinicaltrials.gov) -  Jul 5, 2022   
    P2,  N=15, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Erivedge (vismodegib) / Roche
    Journal:  Metastatic insidious super giant basal cell carcinoma. (Pubmed Central) -  Jul 5, 2022   
    She was treated with Vismodegib, with a remarkable decrease in the size of the cancer...In the setting of progressive disease, medical therapy was switched to cemiplimab instead...Here, we discuss the entity of metastatic super giant basal cell carcinoma; this case is one of the largest reported lesions. As locoregional therapy, such as surgery is sometimes not appropriate for such advanced lesions, we discuss the current forefront of therapy including oral hedgehog pathway and check point inhibitors.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
    Retrospective data, Journal, Monotherapy, PD(L)-1 Biomarker, IO biomarker:  Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50. (Pubmed Central) -  Jun 25, 2022   
    There was no evidence of differences between cemiplimab and pembrolizumab for Grade 3-5 adverse events (AEs) [OR (95% CrI): 1.47 (0.83-2.60)], immune-mediated AEs [1.75 (0.33-7.49)], and all-cause discontinuation due to AEs [1.21 (0.58-2.61)]. Considering the limitations of indirect treatment comparisons, in patients with advanced NSCLC and PD-L1 ⩾50%, cemiplimab monotherapy demonstrated significant improvements in PFS and ORR, comparable OS, and no evidence of differences in safety/tolerability versus pembrolizumab.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1 (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1623;    
    P3
    In this post-hoc analysis, patients with advanced NSCLC across multiple PD-L1 ≥50% subgroups, CEMI resulted in significant overall improvement and delayed TTD in GHS/QoL and multiple patient-reported cancer-related and lung cancer-specific functions and symptoms. Positive PRO results further support the favourable benefit-risk profile of CEMI monotherapy versus CHEMO in advanced NSCLC across all the subgroups with PD-L1 ≥50%.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase II, Journal, Real-world evidence:  Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center. (Pubmed Central) -  Jun 24, 2022   
    PFS was 5.9 months, with a median follow-up was 9 months. In conclusion, cemiplimab demonstrated its utility in the treatment of advanced cSCC, with acceptable response rates, a remarkable number of complete responses, and a very good safety profile.
  • ||||||||||  CP-506 / Convert Pharma
    Trial completion date, Trial primary completion date, Monotherapy, Pan tumor:  Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov) -  Jun 24, 2022   
    P1/2,  N=126, Not yet recruiting, 
    In conclusion, cemiplimab demonstrated its utility in the treatment of advanced cSCC, with acceptable response rates, a remarkable number of complete responses, and a very good safety profile. Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> Feb 2026
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Bullous pemphigoid secondary to cemiplimab: challenges in management () -  Jun 23, 2022 - Abstract #BAD2022BAD_125;    
    Both areas have a paucity of evidence, with a number of agents suggested based on case reports; series. We hope that by highlighting these types of cases dermatology departments will consider their own available treatment pathways in this context.
  • ||||||||||  ASP8374 - Astellas, Dana / Farber Cancer Institute
    Trial primary completion date:  ASP8374 + Cemiplimab in Recurrent Glioma (clinicaltrials.gov) -  Jun 22, 2022   
    P1,  N=24, Recruiting, 
    No abstract available Trial primary completion date: Jun 2022 --> Oct 2022
  • ||||||||||  6-thio-2?-Deoxyguanosine (THIO) / MAIA Biotech, Libtayo (cemiplimab-rwlc) / Regeneron
    Enrollment open, IO biomarker, Metastases:  THIO-101: THIO Sequenced With Cemiplimab in Advanced NSCLC (clinicaltrials.gov) -  Jun 21, 2022   
    P2,  N=182, Recruiting, 
    Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022 Not yet recruiting --> Recruiting
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    The Role of Immunotherapy in the Treatment of Cutaneous Squamous Cell Carcinoma (e-Poster Hall) -  Jun 13, 2022 - Abstract #EADVSp2022EADV_Sp_143;    
    All three drugs have an acceptable safety profile. Whether response can be based on factors such as PD-L1 expression is equivocal.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
    FDA event, Review, Journal:  FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC. (Pubmed Central) -  Jun 4, 2022   
    The consistent survival benefits and manageable toxicity profiles of these single agent anti-PD-(L)-1 antibodies have established them as important treatment options in the PD-L1 high NSCLC treatment landscape. FDA approvals of these anti-PD-(L)-1 antibodies, based on their favorable benefit-risk profiles, present effective chemotherapy-free therapeutic options for patients with advanced PD-L1 high NSCLC in the United States.
  • ||||||||||  Review, Journal, Checkpoint inhibition, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Immune Checkpoint Inhibitors in Cancer Therapy. (Pubmed Central) -  Jun 4, 2022   
    Unfortunately, not all patients respond favourably to these drugs, highlighting the role of biomarkers such as Tumour mutation burden (TMB), PDL-1 expression, microbiome, hypoxia, interferon-γ, and ECM in predicting responses to ICIs-based immunotherapy. The current study aims to review the literature and updates on ICIs in cancer therapy.
  • ||||||||||  Journal:  Combinational therapies for the treatment of advanced cervical cancer. (Pubmed Central) -  Jun 4, 2022   
    : Survival outcomes for advanced cervical cancer patients have been steadily improving since 1981, when single-agent cisplatin was adopted as the standard of care...In 2021, the checkpoint inhibitor (CPI) pembrolizumab, when used in the first line added to platinum-paclitaxel-bevacizumab, increased mOS to 24 months...As for second-line therapy, cemiplimab has shown increased survival compared to single-agent chemotherapy, and a phase III trial with tisotumab vedotin is currently ongoing. Nevertheless, there is still an unmet need for new more effective treatments and significant efforts are needed in the discovery of drugs for advanced cervical cancer beyond the current "me-too" drugs.